Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials
Tóm tắt
Từ khóa
Tài liệu tham khảo
Anonymous: PACT – Cardiovascular prescribing. Prescription Pricing Authority. 2002
Shepherd J: The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. Am J Cardiol. 1995, 76 (9): 113C-7C. 10.1016/S0002-9149(99)80480-9.
Anonymous: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994, 344 (8934): 1383-9. 10.1016/S0140-6736(94)90566-5.
Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996, 335 (14): 1001-9. 10.1056/NEJM199610033351401.
Primatesta P, Poulter NR: Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ. 2000, 321 (7272): 1322-5. 10.1136/bmj.321.7272.1322.
Haq IU, Ramsay LE, Wallis E, et al: Population implications of lipid lowering for prevention of coronary heart disease: data from the 1995 Scottish health survey. Heart. 2001, 86 (3): 289-95. 10.1136/heart.86.3.289.
Harrop J, Donnelly R, Rowbottom A, et al: Improvements in total mortality and lipid levels after acute myocardial infarction in an English health district (1995–1999). Heart. 2002, 87 (5): 428-31. 10.1136/heart.87.5.428.
Kong SX, et al: Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: A meta-analysis of clinical trials. Clin Ther. 1997, 19: 778-97. 10.1016/S0149-2918(97)80102-6.
Hebert PR, Gaziano JM, Chan KS, Hennekens CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA. 1997, 278 (4): 313-21. 10.1001/jama.278.4.313.
Law MR, Wald NJ, Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J. 2003, 326 (7404): 1423-10.1136/bmj.326.7404.1423.
Schulz KF, Grimes DA, Altman DG, Hayes RJ: Blinding and exclusions after allocation in randomised controlled trials: survey of published parallel group trials in obstetrics and gynaecology. Br Med J. 1996, 312: 742-4.
Carroll D, Tramer M, McQuay H, et al: Randomization is important in studies with pain outcomes: Systematic review of transcutaneous electrical nerve stimulation in acute postoperative pain. Br J Anaesth. 1996, 77 (6): 798-803.
Moher D, Cook DJ, Eastwood S, et al: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet. 1999, 354: 1896-1900. 10.1016/S0140-6736(99)04149-5.
Olsson A, Istad H, Luurila O, et al: Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J. 2002, 144: 1044-1051. 10.1067/mhj.2002.128049.
Brown WV, Bays H, Hassman D, et al: Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial. Am Heart J. 2002, 144: 1036-1043. 10.1067/mhj.2002.129312.
Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4.
Gavaghan DJ, Moore RA, McQuay HJ: An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data. Pain. 2000, 85: 415-24. 10.1016/S0304-3959(99)00302-4.
Sterne JA, Gavaghan D, Egger M: Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000, 53 (11): 1119-29. 10.1016/S0895-4356(00)00242-0.
Tang JL, Liu JLY: Misleading funnel plot for detection of bias in meta-analysis. J Clin Epidemiol. 2000, 53: 477-84. 10.1016/S0895-4356(99)00204-8.
Pignone M, Phillips C, Mulrow C: Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. Br Med J. 321 (7267): 983-986. 2000 October 21
Khan KS, Daya S, Jadad AR: The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med. 1996, 156: 661-666. 10.1001/archinte.156.6.661.
Gotto AM, Grundy SM: Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial Data. Issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting. Circulation. 1999, 99 (8): E1-7.
Fenske TK: Lipid-lowering update 2001. Aggressive new goals. Can Fam Physician. 2001, 47: 303-9.
Pearson TA, Laurora I, Chu H, Kafonek S: The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000, 160 (4): 459-67. 10.1001/archinte.160.4.459.
Moore RA, Edwards J, McQuay H: Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports. BMC Urol. 2002, 2: 6-10.1186/1471-2490-2-6.
Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ: Size is everything – large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain. 1998, 78 (3): 209-16. 10.1016/S0304-3959(98)00140-7.
Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH: Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology. 2001, 12 (5): 565-9. 10.1097/00001648-200109000-00017.